Detail akcie CDT Equity Rg online

Business Summary: CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CDT Equity Inc revenues was not reported. Net loss increased 19% to $18.3M. Higher net loss reflects General and administrative expenses increase of 30% to $11.3M (expense), Research and development expenses increase of 45% to $4.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$904.06 to -$215.78.